The Investor’s role in the fight against AMR: Investing responsibly to maximise impact

Antimicrobial resistance (AMR) is not only a threat to public health, with millions of deaths from drug-resistant infections occurring each year, but also to the stability of the global economy. The complexity and cost of care associated with drug-resistant infections contributes to trillions of dollars in annual GDP losses, and the impact is only expected to grow. 

Following last year’s High-Level Meeting on AMR at the United Nations General Assembly, which underlined the importance of cross-sector collaboration in addressing the crisis, it is clear that the collective response is still too fragmented and a more coordinated effort is needed. 

Investors are increasingly recognising AMR as both a material financial risk and a critical sustainability priority. By leveraging their influence on the pharmaceutical industry, they have the power to drive company accountability and help reinforce global commitments that will lead to real progress in the fight against AMR. 

About the webinar 

In partnership with the World Health Organization (WHO), the Foundation is hosting a live webinar entitled ‘The Investor’s role in the fight against AMR: Investing responsibly to maximise impact.’ The session will cover: 

• AMR’s implications for market resilience and long-term investment returns 

• How pharmaceutical companies are addressing AMR, including best practices and ongoing initiatives 

• Areas where more action is needed and how investors can accelerate company action within those areas 

• Practical solutions and accountability mechanisms that can be used to evaluate companies’ performance on AMR and ensure commitments turn into measurable impact 

The event has now passed.

Watch the discussion from the 2025 WAAW webinar